Screener
Aurinia Pharmaceuticals AUPH Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | (5,031) | (17,136) |
| Deferred revenue | 1,705 | 5,147 |
| Operating lease liabilities | (441) | (395) |
| Cash flows from operating activities | 85,126 | 45,541 |
| Cash flows from investing activities: | ||
| Proceeds from the sale and maturities of investments | 209,000 | 255,285 |
| Purchases of investments | (150,805) | (237,411) |
| Net cash and cash equivalents acquired in acquisition of Kezar | 5,212 | — |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's operating cash flow?
- Aurinia Pharmaceuticals (AUPH) reported operating cash flow of $52.57M in Q2 2026.
- How has Aurinia Pharmaceuticals's operating cash flow changed year-over-year?
- Aurinia Pharmaceuticals's operating cash flow increased by 18.8% year-over-year, from $44.24M to $52.57M.
- What is the long-term trend for Aurinia Pharmaceuticals's operating cash flow?
- Over 2 years (2021 to 2025), Aurinia Pharmaceuticals's operating cash flow has grown at a -7.2% compound annual growth rate (CAGR), from -$157.69M to $135.66M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Aurinia Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude